ABEO Share Price Performance
US$5.44
-0.25 (-4.39%)
73.6% undervalued intrinsic discount
US$20.64
Fair Value
Price US$5.44
AnalystConsensusTarget US$20.64
AnalystHighTarget US$28.00
Fair ValueUS$20.64
Share Pricen/a
Abeona Therapeutics Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 31 Fair Values set on narratives written by author
ABEO Community Narratives
AN
Fair Value US$20.64 73.6% undervalued intrinsic discount
Gene Therapy Pipeline Expansion And Reimbursement Progress Will Drive Long Term Upside
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value US$28 80.6% undervalued intrinsic discount
Gene Therapy Adoption And Payer Coverage Will Drive Powerful Long Term Upside
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Gene Therapy Adoption And Payer Coverage Will Drive Powerful Long Term Upside
Catalysts About Abeona Therapeutics Abeona Therapeutics is a biotechnology company focused on developing and commercializing cell and gene therapies for rare and serious diseases. What are the underlying business or industry changes driving this perspective?Read more
3
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$28
80.6% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
881.14% p.a.
Profit Margin
33.94%
Future PE
17.84x
Price in 2028
US$30.33
Gene Therapy Pipeline Expansion And Reimbursement Progress Will Drive Long Term Upside
Catalysts About Abeona Therapeutics Abeona Therapeutics is a commercial stage biotech company developing and manufacturing gene and cell therapies for patients with severe rare diseases. What are the underlying business or industry changes driving this perspective?Read more
27
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$20.64
73.6% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
760.02% p.a.
Profit Margin
0.31%
Future PE
21.53x
Price in 2028
US$0.22
Trending Discussion
Recently Updated Narratives
AN
Gene Therapy Adoption And Payer Coverage Will Drive Powerful Long Term Upside
Fair Value: US$28 80.6% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Gene Therapy Pipeline Expansion And Reimbursement Progress Will Drive Long Term Upside
Fair Value: US$20.64 73.6% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Abeona Therapeutics Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- 1.52
- -7,320.50%
- 20,587.50%
- 11.5%
About ABEO
- Founded
- 1974
- Employees
- 136
- CEO
- WebsiteView website
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
